GlassScriptPhysician profile
Tien Nguyen
NPI 1700361276
$7,524.39
in general payments reported to CMS, 2019-2025
14 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.78 · 2023: $19.12 · 2024: $6,997 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,813 · Food and Beverage: $1,229 · Travel and Lodging: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,812.50 |
| Food and Beverage | $1,228.94 |
| Travel and Lodging | $465.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $6,647.66 | 2024 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $142.10 | 2024-2025 | |
| Janssen Biotech, INC. | $119.04 | 2025 | Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $108.16 | 2024 | Tezspire |
| Exact Sciences Corporation | $105.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $93.35 | 2024-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.55 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $65.50 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $40.76 | 2024-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.43 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $29.94 | 2025 | Rexulti |
| Verona Pharma, INC. | $24.13 | 2025 | Ohtuvayre |
| Nevro Corp. | $19.12 | 2023 | Senza |
| Hikma Pharmaceuticals USA | $17.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tien Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.